S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:GALT

Galectin Therapeutics (GALT) Stock Price, News & Analysis

$2.41
+0.04 (+1.69%)
(As of 03/27/2024 ET)
Today's Range
$2.35
$2.42
50-Day Range
$1.60
$2.44
52-Week Range
$1.28
$2.48
Volume
82,953 shs
Average Volume
109,338 shs
Market Capitalization
$149.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Galectin Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
356.4% Upside
$11.00 Price Target
Short Interest
Bearish
5.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Galectin Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$895 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.74) to ($0.66) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.11 out of 5 stars

Medical Sector

602nd out of 939 stocks

Pharmaceutical Preparations Industry

279th out of 431 stocks

GALT stock logo

About Galectin Therapeutics Stock (NASDAQ:GALT)

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

GALT Stock Price History

GALT Stock News Headlines

Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
GALT Galectin Therapeutics Inc.
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Galectin Therapeutics GAAP EPS of -$0.24
Galectin Therapeutics: Q3 Earnings Insights
Galectin Therapeutics Inc. (PHPN.F)
See More Headlines
Receive GALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/27/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GALT
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+356.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-38,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.58) per share

Miscellaneous

Free Float
29,255,000
Market Cap
$149.06 million
Optionable
Optionable
Beta
0.82
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Joel Lewis (Age 54)
    President, CEO & Director
    Comp: $870.66k
  • Mr. Jack W. Callicutt CPA (Age 57)
    CFO, Treasurer & Corporate Secretary
    Comp: $492.62k
  • Dr. Pol F. Boudes M.D. (Age 67)
    Ph.D., Chief Medical Officer
    Comp: $720.64k
  • Robert Tritt
    General Counsel
  • Mr. Jeff Katstra
    Head of CMC & Pharmaceutical Development
  • Ms. Beth Knowles
    Executive Assistant & Officer Manager

GALT Stock Analysis - Frequently Asked Questions

Should I buy or sell Galectin Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GALT shares.
View GALT analyst ratings
or view top-rated stocks.

What is Galectin Therapeutics' stock price target for 2024?

1 brokerages have issued twelve-month price objectives for Galectin Therapeutics' stock. Their GALT share price targets range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 356.4% from the stock's current price.
View analysts price targets for GALT
or view top-rated stocks among Wall Street analysts.

How have GALT shares performed in 2024?

Galectin Therapeutics' stock was trading at $1.66 at the beginning of the year. Since then, GALT shares have increased by 45.2% and is now trading at $2.41.
View the best growth stocks for 2024 here
.

When is Galectin Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our GALT earnings forecast
.

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04.

What ETFs hold Galectin Therapeutics' stock?

ETFs with the largest weight of Galectin Therapeutics (NASDAQ:GALT) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX),

What other stocks do shareholders of Galectin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Novavax (NVAX), Verastem (VSTM) and Immunomedics (IMMU).

Who are Galectin Therapeutics' major shareholders?

Galectin Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Atria Wealth Solutions Inc. (0.40%), Cambridge Investment Research Advisors Inc. (0.20%), Cutter & CO Brokerage Inc. (0.19%), Solutions 4 Wealth Ltd (0.06%), Beacon Capital Management LLC (0.04%) and Retirement Guys Formula LLC (0.03%). Insiders that own company stock include Elissa J Schwartz, Fund LP 10X, Jack W Callicutt, Joel Lewis, Kary Eldred, Kevin D Freeman and Richard A Jr Zordani.
View institutional ownership trends
.

How do I buy shares of Galectin Therapeutics?

Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GALT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners